Enanta Pharmaceuticals (ENTA) EBT (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of EBT data on file, last reported at -$13.1 million in Q1 2026.

• Quarterly EBT rose 45.37% year-over-year to -$13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$61.9 million (up 37.42% YoY) and the FY2025 annual result came in at -$83.5 million, up 29.07% from the prior year.
• EBT fell to -$13.1 million in Q1 2026, from -$11.9 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$11.9 million in Q4 2025 to a low of -$37.6 million in Q1 2023.
• A 5-year average of -$26.4 million and a median of -$29.0 million in 2022 frame the typical range for EBT.
• Annual changes were most pronounced in 2023 — EBT decreased 17.26% — and 2025, when it soared 47.53%.
• Tracing ENTA's EBT over 5 years: stood at -$29.0 million in 2022, then slipped by 17.26% to -$34.0 million in 2023, then soared by 33.27% to -$22.7 million in 2024, then soared by 47.53% to -$11.9 million in 2025, then decreased by 9.82% to -$13.1 million in 2026.
• The last three EBT figures came in at -$13.1 million (Q1 2026), -$11.9 million (Q4 2025), and -$18.7 million (Q3 2025), per Business Quant data.